Form 4: FibroBiologics CEO Pete O'Heeron Reports Stock Transaction

FibroBiologics CEO Pete O'Heeron reported a disposition of 50,000 common shares on December 3, 2024, resulting in a total beneficial ownership of 6,006,647 shares.

Summary

• FibroBiologics CEO, Pete O'Heeron, reported a transaction involving the company's stock.
• On December 3, 2024, Mr. O'Heeron disposed of 50,000 shares of common stock.
• The disposition was a gift, with a price of $0 per share.
• Following the transaction, Mr. O'Heeron's total beneficial ownership is 6,006,647 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to an insider stock transaction. It doesn't indicate any positive or negative sentiment about the company's performance or future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is required when company insiders trade their company's stock. These filings are common and provide transparency into insider transactions.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for all publicly traded companies in the United States.
• The reporting requirements are consistent across all companies, ensuring transparency in insider trading activities.
• The transaction itself is not unusual, as executives often receive or dispose of shares as part of their compensation or personal financial planning.

Stakeholder Impact

• The transaction may be of interest to shareholders as it provides insight into the actions of the company's CEO.
• The transaction is unlikely to have a significant impact on other stakeholders.

Key Dates

Keywords

FibroBiologics, FBLG, Pete O'Heeron, stock transaction, beneficial ownership, SEC Form 4, insider trading